JP2008050367A5 - - Google Patents

Download PDF

Info

Publication number
JP2008050367A5
JP2008050367A5 JP2007287366A JP2007287366A JP2008050367A5 JP 2008050367 A5 JP2008050367 A5 JP 2008050367A5 JP 2007287366 A JP2007287366 A JP 2007287366A JP 2007287366 A JP2007287366 A JP 2007287366A JP 2008050367 A5 JP2008050367 A5 JP 2008050367A5
Authority
JP
Japan
Prior art keywords
composition according
patient
cardiovascular
composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007287366A
Other languages
English (en)
Japanese (ja)
Other versions
JP5134916B2 (ja
JP2008050367A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2007287366A priority Critical patent/JP5134916B2/ja
Priority claimed from JP2007287366A external-priority patent/JP5134916B2/ja
Publication of JP2008050367A publication Critical patent/JP2008050367A/ja
Publication of JP2008050367A5 publication Critical patent/JP2008050367A5/ja
Application granted granted Critical
Publication of JP5134916B2 publication Critical patent/JP5134916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007287366A 2005-07-08 2007-11-05 心血管イベント発症予防用組成物 Active JP5134916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007287366A JP5134916B2 (ja) 2005-07-08 2007-11-05 心血管イベント発症予防用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005200503 2005-07-08
JP2005200503 2005-07-08
JP2007287366A JP5134916B2 (ja) 2005-07-08 2007-11-05 心血管イベント発症予防用組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006188456A Division JP4751257B2 (ja) 2005-07-08 2006-07-07 心血管イベント発症予防用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012157914A Division JP5809115B2 (ja) 2005-07-08 2012-07-13 心血管イベント予防用製剤

Publications (3)

Publication Number Publication Date
JP2008050367A JP2008050367A (ja) 2008-03-06
JP2008050367A5 true JP2008050367A5 (https=) 2009-08-13
JP5134916B2 JP5134916B2 (ja) 2013-01-30

Family

ID=39234724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007287366A Active JP5134916B2 (ja) 2005-07-08 2007-11-05 心血管イベント発症予防用組成物

Country Status (1)

Country Link
JP (1) JP5134916B2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
JP4751257B2 (ja) * 2005-07-08 2011-08-17 持田製薬株式会社 心血管イベント発症予防用組成物

Similar Documents

Publication Publication Date Title
JP2008050367A5 (https=)
JP5809115B2 (ja) 心血管イベント予防用製剤
John et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients
JP5134916B2 (ja) 心血管イベント発症予防用組成物
Chew et al. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis’
ES2632967T3 (es) Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
Morgan et al. Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure
US20080299187A1 (en) Substances for Reducing Occurence of Major Cardiac Events in Humans
JPWO2009142242A1 (ja) ハイリスク患者の心血管イベント予防用組成物
McCarty Policosanol safely down-regulates HMG-CoA reductase–potential as a component of the Esselstyn regimen
CN109152760B (zh) 胆汁淤积性和纤维化疾病的治疗方法
Kandula et al. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases
JP2007238598A (ja) 脳卒中再発予防用組成物
US20120282359A1 (en) Compositions, Kits, and Methods for the Treatment of Conditions Associated with Elevated Cholesterol Levels
EP1045691A1 (en) Statin-carboxyalkylether combinations
WO2009059717A2 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
JP5226980B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物
JP2007238594A (ja) 脳卒中再発予防用組成物
JP4751257B2 (ja) 心血管イベント発症予防用組成物
JP2014509305A5 (https=)
JP4949661B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
JP5171073B2 (ja) 循環器系疾患の予防又は治療のための医薬組成物
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
MX2007006092A (es) Composiciones farmaceuticas que comprenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg-coa reductasa.
JP2006176498A5 (https=)